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Background
The current goal of antiretroviral treatment (ART) is to
achieve and maintain virological suppression below limits
of detection (<50 copies/mL). Despite a potent ART,
some patients experience persistently low viral loads
(VL), between 50-1000 copies/mL. The long-term conse-
quences of persistent low-level viremia (LLV) are nega-
tive, usually predicting a virological failure.
Methods
A cohort, retrospective study was conducted in Adult
Clinic I of the National Institute for Infectious Diseases
“Prof. Dr. Matei Balş”, Bucharest, over a 6 year-period
(01.2008-12.2013). The main inclusion criteria were:
HIV-positive patients stable on ART (>6 months) at their
first regimen, good adherence and absence of other medi-
cation susceptible for drug-drug interactions with ART.
We recorded the demographical data (age/gender), the
HIV transmission route, CDC stage, the baseline
immune-virological status (CD4 count, HIV-VL and gen-
otypic mutations) and ART regimen. There were also
registered subsequently CD4 count and HIV-VL (biannu-
ally taken). We then analyzed the management of the
patients found with LLV: maintaining the current
ART regimen and close monitoring, ART intensifi-
cation or ART switch. LLV was defined as VL >50 and
<1000 copies/mL in at least 2 determinations over a
24 week-period, after at least 24 weeks of stable ART.
Results
Of 61 patients screened, 35 met the inclusion criteria.
The median age was 38 years, (IQR, 32-51) and 71.4%
(n = 25) were male. According to 1993 CDC classifica-
tion, 42.8% (n = 15) were A2 and 22.8% (n = 8) were
C3. Sixty percent (n = 21) were heterosexually infected.
The median baseline CD4 count was 292 cells/cmm
(IQR, 179-376), and median VL was 5.1 log10 copies/mL
(IQR, 4.4-5.4). Two patients had detectable baseline
mutations. All ART regimens contained 2 NRTI plus
one as following: boosted-lopinavir (11 patients), efavir-
enz (10 patients), boosted-darunavir (6 patients), boosted-
atazanavir (5 patients) and raltegravir (3 patients). Of
11 patients (31.4%) who had detectable VL at 6 months,
5 met the LLV definition criteria. Their median VL was
267 copies/mL and the median CD4 count was 551/cmm.
None of them had had baseline mutations. They didn’t
have changes in the current ART regimen, except one
patient in whom we increased darunavir dose to 1200 mg/
day. At 12 months their median CD4 count raised to
743/cmm and the median VL declined to 150 copies/mL.
Conclusion
Although none of the patients with LLV became unde-
tectable at 12 months of treatment, their VL levels
decreased progressively in line with the increase in CD4
count in the absence of ART changing.
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